Profile: AVI Biopharma, Inc. is focused on the development of RNA–based drugs. We offer Translation Suppressing™, and Splice Switching Oligomers™. The Translation Suppressing Oligomers are PMO based anti sense compounds, that interfere with gene expression or other mRNA–dependent cellular processes, by binding to their specific target sequence in mRNA. These have high mRNA binding and act by a simple steric–blocking mechanism, instead of by RNAse H–mediated or RISC–mediated mRNA degradation. Our Splice Switching Oligomers are also PMO based compounds, that can direct alternative splicing by forcing the cellular splicing machinery towards desired pathways. These are designed to block disease related splicing pathways, and simultaneously promote the production of desired mRNAs and their proteins.

The company was founded in 1980, has revenues of < USD 1 Million, has ~120 employees. NASDAQ:AVII (SEC Filings)